ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited [TSE:4502/NYSE:TAK] (“Takeda”) today announced that they have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for the treatment of acute inflammatory conditions.
| PROVIDENCE, R.I., and OSAKA, Japan, April 23, 2020 /PRNewswire/ -- ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited [TSE:4502/NYSE:TAK] (“Takeda”) today announced that they have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for the treatment of acute inflammatory conditions. Early research has indicated that this IAIP technology has the potential to deliver a highly innovative, disease-modifying treatment for a range of acute inflammatory diseases. In such conditions, dysregulated inflammation plays a key role in the pathology, and there are no effective treatments available today. IAIP are naturally occurring proteins that circulate in the blood, and extensive research at ProThera has shown that these proteins play an essential role in human health by controlling inflammation. They exert their anti-inflammatory effects through multiple mechanisms and have the potential to change the paradigm of treatment for patients with dysregulated immune responses. During acute illnesses, however, the levels of these anti-inflammatory proteins rapidly decline. A replenishment strategy for patients using Inter-alpha Inhibitors is supported by numerous preclinical studies. “Our goal is to successfully treat patients with severe inflammatory conditions and this is now possible through our alliance with Takeda,” said Denice Spero, president and chief business officer of ProThera. “Takeda’s R&D expertise is well aligned with the potential uses of our Inter-alpha Inhibitor technology. We are delighted that Takeda and ProThera are collaborating and that Takeda shares our enthusiasm for tackling unmet medical needs.” As part of the agreement, ProThera and Takeda will work together on IND-enabling activities, with development led by Takeda’s dedicated Plasma Derived Therapies R&D organization. The broad collaboration will also explore the development of companion diagnostics with the goal of personalizing patient treatment and maximizing real-world outcomes. Takeda will assume responsibility for funding all development and commercialization activities. The financial terms of the licensing agreement are not being disclosed. “We believe ProThera’s expertise in IAIP technology represents a potentially powerful opportunity to explore the untapped potential of plasma in order to address challenging rare and complex diseases,” commented Dr. Chris Morabito, Takeda’s Head of Research and Development, Plasma-Derived Therapies Business Unit. “Leveraging this potent technology using our deep expertise and robust dedicated plasma infrastructure, this collaboration reflects our patient-centered R&D efforts and could represent an important new avenue to deliver meaningful innovation to patient populations in need.” “ProThera is proud to join forces with a world-class company like Takeda to tackle a number of challenging diseases. Takeda is one of the leaders in plasma-derived therapies, and we are confident that this partnership may advance this promising therapeutic into the clinic,” said Dr. Yow-Pin Lim, co-founder and CEO of ProThera. “It has been a long journey to study these extraordinary proteins, and we are excited about the possibilities of achieving positive clinical outcomes.” About ProThera Biologics ProThera Biologics has focused since inception on developing Inter-alpha Inhibitor Proteins for the treatment of life-threatening inflammatory diseases along with a rapid, point of care diagnostic test to determine IAIP levels for use as a biomarker for patient progression to severe outcomes. ProThera has demonstrated the potential of IAIP therapy in numerous preclinical models and the use of IAIP as a biomarker in clinical samples. The company was co-founded by Yow-Pin Lim, M.D., Ph.D., and Douglas Hixson, Ph.D., faculty members at the Warren Alpert Medical School of Brown University, based upon research originating in the labs at Lifespan/Rhode Island Hospital, with seed funding from the R.I.-based Slater Technology Fund. In developing its technology, ProThera has collaborated with investigators at multiple academic research institutions and has been awarded in excess of $12 million in federal funding from agencies within the National Institutes of Health pursuant to Small Business Investment Research (SBIR) grants. The company has received continued investment from the Slater Fund, and has also received support from R.I. Commerce Corp. through its Innovate RI Small Business Fund. Approximately $4M in Phase II SBIR grants from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Allergy and Infectious Disease (NIAID) is currently supporting collaborative research with Care New England/Women & Infants Hospital on neonatal brain injury as well as the rapid test to assist therapy in infants with life-threatening diseases. About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com. Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. SOURCE ProThera Biologics, Inc. | ||
Company Codes: NYSE:TAK, Tokyo:4502 |
View original content:
